Foghorn Therapeutics Inc. (FHTX)
Chart Events
Performance Outlook
| Previous Close | 4.5700 |
| Open | 4.5700 |
| Bid | 4.5100 x 1100 |
| Ask | 4.6000 x 1000 |
| Day's Range | 4.4900 - 4.6000 |
| 52 Week Range | 2.8400 - 9.9700 |
| Volume | |
| Avg. Volume | 97,985 |
| Market Cap | 192.51M |
| Beta (5Y Monthly) | 2.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4600 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FHTX
Related Research
- Foghorn Therapeutics Inc.Daily – Vickers Top Buyers & Sellers for 11/07/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat28 days agoArgus Research
GlobeNewswireFoghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held
Simply Wall St.Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 27...
PR NewswireFlagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo
